On April 27, 2026, Veradermics (NYSE: MANE) released positive topline data from Study ‘302’ — the first of two pivotal Phase 2/3 trials evaluating VDPHL01, the company’s extended-release oral minoxidil tablet. The results met every primary and key secondary endpoint, and sent shares surging 48% in a single trading session.
For the estimated 50 million men in the United States living with pattern hair loss — and the physicians who treat them — the data represent something that has not existed in nearly three decades: a credible new oral treatment option designed from the ground up for their condition.
What the Trial Showed
Study ‘302’ enrolled 519 men with mild-to-moderate androgenetic alopecia in a randomized, double-blind, placebo-controlled design. Participants were assigned to one of three groups: VDPHL01 8.5 mg once daily (QD), VDPHL01 8.5 mg twice daily (BID), or placebo. The primary treatment period ran six months.
The co-primary endpoints — objective hair count and patient-reported improvement — were both met with high statistical significance (p<0.0001) in both active treatment arms.
Hair Count (Non-Vellus Target Area Hair Count at Month 6)
| Group | Mean Increase (hairs/cm²) | p-value vs. placebo |
|---|---|---|
| VDPHL01 once daily (QD) | +30.3 | <0.0001 |
| VDPHL01 twice daily (BID) | +33.0 | <0.0001 |
| Placebo | +7.3 | — |
Patient-Reported Outcomes (AAIRS Scale)
Among patients reporting any improvement in hair coverage at Month 6:
- 79.3% — VDPHL01 once daily
- 86.0% — VDPHL01 twice daily
- 35.6% — Placebo
Among patients reporting they felt “improved” or “much improved”:
- 48.4% — VDPHL01 QD (vs. 13.4% placebo; p<0.0001)
- 62.9% — VDPHL01 BID (vs. 13.4% placebo; p<0.0001)
Independent of what patients reported, treating investigators reached the same conclusion: 72.0% (QD) and 84.4% (BID) of patients were graded as having improved hair coverage at Month 6 — numbers that closely mirror the patient-reported data.
One Detail That Stands Out: It Worked Fast
Perhaps the most clinically meaningful secondary finding was speed of onset. Statistically significant separation from placebo on both hair count and investigator assessment was observed as early as Month 2 — the earliest time point measured in the trial.
For patients who have cycled through topical treatments with slow or uncertain results, early visible response matters enormously. Adherence to any chronic therapy depends heavily on whether patients see something happening — and Month 2 is a very different conversation from Month 6.
What About Cardiac Safety?
Oral minoxidil carries a well-documented cardiovascular liability in its immediate-release form. High peak plasma concentrations are associated with fluid retention, pericardial effusion, and serious cardiac events at higher doses. That ceiling has historically limited how aggressively physicians were willing to use oral minoxidil off-label.
VDPHL01’s extended-release gel matrix technology was engineered specifically to flatten that peak while extending the time the drug remains above the hair-growth threshold. Study ‘302’ safety data reflect that design intent:
- No treatment-related serious adverse events (SAEs)
- No adverse events of special interest (AESIs) of cardiac origin
- Adverse event-related discontinuation rates similar to placebo
- Overall treatment-emergent adverse event (TEAE) rates comparable between VDPHL01 and placebo throughout Month 6
What Experts Are Saying
“Dermatology has been treating hair loss with a drug borrowed from cardiology, in a formulation never intended for our patients, at doses we arrived at informally. VDPHL01 is the first oral minoxidil formulation developed specifically for pattern hair loss, and now the first to generate positive Phase 3 results of efficacy and safety.”
Dr. Michael Gold, Study ‘302’ trial investigator, board-certified dermatologist
“I believe that an oral therapy that has improved hair loss in the eyes of nearly 80% of patients and investigators, was generally well tolerated in trials and sits in a class that dermatologists are already comfortable prescribing, has the potential to transform the treatment landscape for male pattern hair loss.”
Dr. Maryanne Makredes Senna, Assistant Professor of Dermatology, Harvard Medical School; Member, Veradermics Scientific Advisory Board
“With a formulation designed to deliver more consistent exposure and avoid peak concentrations associated with dose-limiting cardiac side effects, we believe VDPHL01 has a potentially differentiated, generally well tolerated clinical profile with rapid, consistent, and robust hair growth. We are optimistic that these results represent a defining milestone for the hair loss community.”
Reid Waldman, M.D., Chief Executive Officer, Veradermics
What Comes Next
Study ‘302’ is the first of three pivotal trials in Veradermics’ development program. A confirmatory male trial (Study ‘304’, 536 patients) is fully enrolled with results due H2 2026, and a women’s trial (Study ‘306’) is actively recruiting. Read our full breakdown of the FDA roadmap and the women’s trial →
The Bigger Picture
Pattern hair loss affects an estimated 80 million Americans — 50 million men and 30 million women. The last FDA-approved prescription treatment for the condition reached the market nearly 30 years ago. Since then, physicians have managed patients with off-label formulations of oral minoxidil — a use that was never formally studied at scale, never optimized for the scalp, and never validated in the kind of controlled trial that just read out for VDPHL01.
Wall Street took note immediately: Veradermics shares rose 48% on the day of the announcement. Analysts at Cantor described the results as a “home run” and “best case scenario,” with peak U.S. sales projections of $1.5–2 billion. The global pattern hair loss market is projected to reach approximately $30 billion by 2028.
Whether those projections prove accurate depends on what Study ‘304’ delivers later this year. But Study ‘302’ has established something that was missing from this field for three decades: Phase 3-level evidence for an oral treatment purpose-built for hair loss.
Sources: Veradermics press release via Business Wire (April 27, 2026); BioPharma Dive; STAT News.